Research progress of antibody-drug conjugates therapy for HER2-low expressing gastric cancer
Minghui Yu1, Yangyueying Liang1, Longhui Li1
1Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Anshanxi Road, Nankai District, Tianjin 300193, China; National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, China.
Abstract:
Gastric cancer (GC) is a highly fatal malignant tumor in the world. Most of the patients are in an unresectable state when they have symptoms. Systemic treatment is the primary treatment for advanced patients. Among them, the Human epidermal growth factor receptor 2 (HER2) is an important therapeutic target. With the continuous optimization of chemotherapeutic drugs and chemotherapy regimens, the prognosis of some HER2-positive GC patients has been greatly improved. However, the needs of GC patients with a low level of HER2 expression still need to be met. Several targeted drugs against human epidermal growth factor receptor 2 emerged in recent years, including Antibody-drug Conjugates (ADC), novel humanized anti-HER2 monoclonal antibodies, and Tyrosine kinase inhibitors (TKI). As an important breakthrough in treating HER2-positive GC, ADC became one of the fastest-growing anti-tumor drugs. Some drugs also showed an anti-tumor effect on GC with low expression of HER2. It may also be the key to the treatment of low expression of HER2 GC in the future. This article mainly reviews several promising ADC drugs for the treatment of HER2 low-expression GC and related trials.
Insights
Antibody-drug Conjugates (ADC) show promise for treating gastric cancer (GC) with low Human Epidermal growth factor Receptor 2 (HER2) expression. This review highlights ADCs as a potential breakthrough for this patient group.
Area of Science:
- Oncology
- Pharmacology
Background:
- Gastric cancer (GC) remains a leading cause of cancer mortality worldwide.
- Many patients present with unresectable disease, necessitating systemic treatment.
- Human Epidermal growth factor Receptor 2 (HER2) is a key therapeutic target in advanced GC.
Purpose of the Study:
- To review promising Antibody-drug Conjugates (ADC) for treating HER2-low expressing gastric cancer.
- To discuss the potential of ADCs in addressing unmet needs in HER2-low GC.
Main Methods:
- Review of recent clinical trials and emerging targeted therapies.
- Focus on Antibody-drug Conjugates (ADCs) and their efficacy in HER2-positive and HER2-low GC.
Main Results:
- HER2-targeted therapies, particularly ADCs, have improved outcomes for HER2-positive GC.
- Emerging data suggests ADCs may also be effective against GC with low HER2 expression.
Conclusions:
- ADCs represent a significant advancement in the treatment of HER2-positive GC.
- ADCs hold potential as a future therapeutic strategy for HER2-low expressing gastric cancer.
More Related Videos
07:36Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
